tetano
Editor, Senior Moderator
Vaccine
. 2024 Sep 10;42(26):126355.
doi: 10.1016/j.vaccine.2024.126355. Online ahead of print. Delivery of SARS-CoV-2 spike and membrane genes in a single Baculoviral vector enhance the immune breadth against SARS-CoV-2 variants of concern
Jungmin Chun[SUP] 1 [/SUP], Doyoung Yoon[SUP] 1 [/SUP], Aleksandra Nowakowska[SUP] 1 [/SUP], Hyeon Dong Lee[SUP] 1 [/SUP], Chanyeong Lee[SUP] 1 [/SUP], Jinha Kim[SUP] 1 [/SUP], Sehyun Kim[SUP] 2 [/SUP], Heewon Bang[SUP] 1 [/SUP], Hee-Jung Lee[SUP] 1 [/SUP], Young Bong Kim[SUP] 3 [/SUP]
Affiliations
Although the coronavirus pandemic has ended, new variants of concern (VOCs) continue to emerge. Therefore, novel vaccines targeting VOCs are highly warranted. We initially constructed three recombinant baculovirus-vectored vaccines (AcHERV-COVID19S) carrying the spike genes of the SARS-CoV-2 prototype, Delta, and Omicron BA.1 variants. However, the SARS-CoV-2 spike gene alone could not provide protection against multiple VOCs. To develop a universal vaccine, we constructed a recombinant baculovirus-vectored vaccine (AcHERV-COVID19 OmiM) by introducing the M gene, which is conserved among VOCs, as a secondary cellular immune antigen in addition to the S gene. AcHERV-COVID19 OmiM could provide higher protection against SARS-CoV-2 variants (prototype, Delta, BA.5 and XBB.1) compared with that of AcHERV-COVID19S. The membrane protein of SARS-CoV-2 synergizes with the S gene, thereby enhancing both humoral and cellular immunity against VOCs. Although AcHERV-COVID19 OmiM may not provide sterile protection against new variants, it may help reduce symptoms and curb viral transmission.
Keywords: Baculoviral-vector; COVID-19; Immunogenicity; SARS-CoV-2; Vaccine.
. 2024 Sep 10;42(26):126355.
doi: 10.1016/j.vaccine.2024.126355. Online ahead of print. Delivery of SARS-CoV-2 spike and membrane genes in a single Baculoviral vector enhance the immune breadth against SARS-CoV-2 variants of concern
Jungmin Chun[SUP] 1 [/SUP], Doyoung Yoon[SUP] 1 [/SUP], Aleksandra Nowakowska[SUP] 1 [/SUP], Hyeon Dong Lee[SUP] 1 [/SUP], Chanyeong Lee[SUP] 1 [/SUP], Jinha Kim[SUP] 1 [/SUP], Sehyun Kim[SUP] 2 [/SUP], Heewon Bang[SUP] 1 [/SUP], Hee-Jung Lee[SUP] 1 [/SUP], Young Bong Kim[SUP] 3 [/SUP]
Affiliations
- PMID: 39260058
- DOI: 10.1016/j.vaccine.2024.126355
Although the coronavirus pandemic has ended, new variants of concern (VOCs) continue to emerge. Therefore, novel vaccines targeting VOCs are highly warranted. We initially constructed three recombinant baculovirus-vectored vaccines (AcHERV-COVID19S) carrying the spike genes of the SARS-CoV-2 prototype, Delta, and Omicron BA.1 variants. However, the SARS-CoV-2 spike gene alone could not provide protection against multiple VOCs. To develop a universal vaccine, we constructed a recombinant baculovirus-vectored vaccine (AcHERV-COVID19 OmiM) by introducing the M gene, which is conserved among VOCs, as a secondary cellular immune antigen in addition to the S gene. AcHERV-COVID19 OmiM could provide higher protection against SARS-CoV-2 variants (prototype, Delta, BA.5 and XBB.1) compared with that of AcHERV-COVID19S. The membrane protein of SARS-CoV-2 synergizes with the S gene, thereby enhancing both humoral and cellular immunity against VOCs. Although AcHERV-COVID19 OmiM may not provide sterile protection against new variants, it may help reduce symptoms and curb viral transmission.
Keywords: Baculoviral-vector; COVID-19; Immunogenicity; SARS-CoV-2; Vaccine.